Hims & Hers

Company HIMS

Last mentioned: Mar 12, 2026

Timeline

  1. Global Market Reaction

    Industry analysts note the deal as a major consolidation in the GLP-1 and telehealth sectors.

  2. Payout Details Emerge

    Former CCO Joe Harris confirms a payout exceeding $1 million, highlighting the impact on staff wealth.

  3. Acquisition Announced

    Hims & Hers officially announces the $1.6 billion buyout of Sydney-based Eucalyptus.

Stories mentioning Hims & Hers 2

Health Policy Bearish

FDA Issues Warning to Novo Nordisk Over GLP-1 Adverse Event Reporting

The FDA has issued a formal warning letter to Novo Nordisk for failing to properly report serious adverse events, including deaths and strokes, related to its GLP-1 medications. This regulatory escalation coincides with a significant market valuation decline and intensifying competition from compounding pharmacies.

3 sources
acquisition Bullish

Hims & Hers Acquires Eucalyptus for $1.6B in Global Telehealth Consolidation

US telehealth leader Hims & Hers has finalized a $1.6 billion acquisition of Australian digital health startup Eucalyptus, marking a major expansion into the Asia-Pacific market. The deal, driven by the explosive growth of GLP-1 weight-loss treatments, creates over 100 employee millionaires and solidifies Hims & Hers' position as a global powerhouse in direct-to-consumer healthcare.

2 sources

About Hims & Hers coverage

This page surfaces every story mentioning Hims & Hers across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.

What you seeWhat it tells you
Story countNumber of distinct stories where Hims & Hers was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.